Fludarabine induces apoptosis of human T-cell leukemia virus type 1-infected T cells via inhibition of the nuclear factor-κB signal pathway

Leukemia

Volumn 21, Issue 5, 2007, Pages 1044-1049

  Nishioka, C ^a   Ikezoe, T ^a   Yang, J ^a   Koeffler, H P ^b   Taguchi, H ^a  

^a KOCHI UNIVERSITY   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUDARABINE PHOSPHATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOCORTIN 5; X LINKED INHIBITOR OF APOPTOSIS;

ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; GEL MOBILITY SHIFT ASSAY; GENE TRANSLOCATION; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DNA BINDING; PROTEIN FUNCTION; REPORTER GENE; SIGNAL TRANSDUCTION; T CELL LEUKEMIA; WESTERN BLOTTING;

EID: 34247579723     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404622     Document Type: Article

References (23)

1. Hinuma Y, Nagata K, Hanaoka M, Nakai M, Matsumoto T, Kinoshita KI et al. Adult T-cell leukemia: Antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA 1981; 78: 6476-6480.
2. Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA 1982; 79: 2031-2035.
3. Taguchi H, Kinoshita KI, Takatsuki K, Tomonaga M, Araki K, Arima N et al. An intensive chemotherapy of adult T-cell leukemia/lymphoma: CHOP followed by etoposide, vindesine, ranimustine, and mitoxantrone with granulocyte colony-stimulating factor support. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 12: 182-186.
4. Yamada Y, Tomonaga M, Fukuda H, Hanada S, Utsunomiya A, Tara M et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol 2001; 113: 375-382.
5. Keating MJ, Kantarjian H, Talpaz M, Redman J, Koller C, Barlogie B et al. Fludarabine: A new agent with major activity against chronic lymphocytic leukemia. Blood 1989; 74: 19-25.
6. Plunkett W, Gandhi V, Huang P, Robertson LE, Yang LY, Gregoire V et al. Fludarabine: Pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin Oncol 1993; 20: 2-12.
7. Dasgupta RK, Rule S, Johnson P, Davies J, Burnett A, Poynton C et al. Fludarabine phosphate and melphalan: A reduced intensity conditioning regimen suitable for allogeneic transplantation that maintains the graft versus malignancy effect. Bone Marrow Transplant 2006; 37: 455-461.
8. Aggarwal BB. Nuclear factor-kappaB: The enemy within. Cancer Cell 2004; 6: 203-208.
9. Pikarsky E, Porat RM, Stein I, Avramovitch R, Amit S, Kasem S et al. NF-kappaB functions as tumor promoter in inflammation associated cancer. Nature 2004; 431: 461-466.
10. Baldwin Jr AS. The NF-κB and IκB proteins: New discoveries and insights. Annu Rev Immunol 1996; 14: 649-683.
11. Mori N, Yamada Y, Ikeda S, Yamasaki Y, Tsukasaki K, Tanaka Y et al. Bay 11-7082 inhibits transcription factor NF-kappaB and induces apoptosis of HTLV-1-infected T-cell lines and primary adult T-cell leukemia cells. Blood 2002; 100: 1828-1834.
12. Satou Y, Nosaka K, Koya Y, Yasunaga JI, Toyokuni S, Matsuoka M. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. Leukemia 2004; 18: 1357-1363.
13. Ikezoe T, Yang Y, Bandobashi K, Saito T, Takemoto S, Machida H et al. Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-kappa B signal pathways. Mol Cancer Ther 2005; 4: 578-586.
14. Schimmer AD, Dalili S, Batey RA, Riedl SJ. Targeting XIAP for the treatment of malignancy. Cell Death Differ 2006; 13: 179-188.
15. Nishioka C, Takemoto S, Kataoka S, Yamanaka S, Moriki T, Shoda M et al. Serum level of soluble CD30 correlates with the aggressiveness of adult T-cell leukemia/lymphoma. Cancer Sci 2005; 96: 810-815.
16. Johnson SA. Use of fludarabine in the treatment of mantle cell lymphoma, Waldenstrom's macroglobulinemia and other uncommon B- and T-cell lymphoid malignancies. Hematol J 2004; 5 (Suppl 1): S50-S61.
17. Pahler JC, Ruiz S, Niemer I, Calvert LR, Andreeff M, Keating M et al. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia. Clin Cancer Res 20031; 9: 4570-4577.
18. Kelley TW, Alkan S, Srkalovic G, Hsi ED. Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis. Leuk Res 2004; 28: 845-850.
19. Faderl S, Rai K, Gribben J, Byrd JC, Flinn IW, O'brien S et al. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia. Cancer 2006; 107: 916-924.
20. Quaglino P, Fierro MT, Rossotto GL, Savoia P, Bernengo MG. Treatment of advanced mycosis fungoides/Sezary syndrome with fludarabine and potential adjunctive benefit to subsequent extracorporeal photochemotherapy. Br J Dermatol 2004; 150: 327-336.
21. Go RS, Gazelka H, Hogan JD, Wester SM. Subcutaneous panniculitis-like T-cell lymphoma: Complete remission with fludarabine. Ann Hematol 2003; 82: 247-250.
22. Frank DA, Mahajan S, Ritz J. Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat Med 1999; 5 444-447.
23. Klotz L, Schmidt M, Giese T, Sastre M, Knolle P, Klockgether T et al. Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients. J Immunol 2005; 175: 4948-4955.